西马鲁肽用于超重或无糖尿病的肥胖人群心血管风险降低（新适应症）。

{"title":"西马鲁肽用于超重或无糖尿病的肥胖人群心血管风险降低（新适应症）。","authors":"","doi":"10.18773/austprescr.2025.024","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 3","pages":"107-108"},"PeriodicalIF":3.4000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187477/pdf/","citationCount":"0","resultStr":"{\"title\":\"Semaglutide for cardiovascular risk reduction in people who are overweight or have obesity without diabetes (new indication).\",\"authors\":\"\",\"doi\":\"10.18773/austprescr.2025.024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":55588,\"journal\":{\"name\":\"Australian Prescriber\",\"volume\":\"48 3\",\"pages\":\"107-108\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187477/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Australian Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18773/austprescr.2025.024\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australian Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18773/austprescr.2025.024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}